ATOS (Atossa Therapeutics) 3-1 Month Momentum %: -10.93% (As of Jul. 11, 2026)


ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $2.37
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics 3-1 Month Momentum %?

Atossa Therapeutics ATOS +0.42% 26 3-1 Month Momentum % is -10.93% as of Jul. 11, 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,385 Biotechnology companies, Atossa Therapeutics ranks worse than 51.12% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-11), Atossa Therapeutics's 3-1 Month Momentum % is -10.93%.

The industry rank for Atossa Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

ATOS's 3-1 Month Momentum % is ranked worse than
51.12% of 1385 companies
in the Biotechnology industry
Industry Median: -10.98 vs ATOS: -10.93

Atossa Therapeutics  (NAS:ATOS) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Atossa Therapeutics 3-1 Month Momentum % Related Terms

ATOS vs QNCX, ZIVO, KTTA: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Atossa Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's 3-1 Month Momentum % falls into.


ATOS
26GF Score
Atossa Therapeutics Inc ATOS
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics  (NAS:ATOS) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -10.93% mean?
Atossa Therapeutics (ATOS) has a 3-1 Month Momentum % of -10.93% as of Jul. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Atossa Therapeutics and its competitors. According to the industry distribution chart, Atossa Therapeutics ranks #708 out of 1385 companies in the Biotechnology industry, placing it in the top 51.1%.
Is Atossa Therapeutics' 3-1 Month Momentum % too high?
Atossa Therapeutics' current 3-1 Month Momentum % is -10.93%. Based on the distribution chart, Atossa Therapeutics ranks #708 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' 3-1 Month Momentum % compare to QNCX and ZIVO?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #708 out of 1385 companies for 3-1 Month Momentum %. This places Atossa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Atossa Therapeutics and its competitors. Atossa Therapeutics's current 3-1 Month Momentum % is -10.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current 3-1 Month Momentum % of -10.93%. The current 3-1 Month Momentum % is -10.93%. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current 3-1 Month Momentum % is -10.93% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.37
Price